ReviewWorld journal of urology2022
Active surveillance for intermediate-risk prostate cancer.
Madhur Nayan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
ReviewWorld journal of urology2022
Madhur Nayan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.